Multitarget Profiling of a Strigolactone Analogue for Early Events of Alzheimer's Disease: In Vitro Therapeutic Activities against Neuroinflammation

Basit Öğe Kaydı
dc.authoridTumer, Tugba/0000-0002-1740-4867
dc.authoridOzleyen, Adem/0000-0003-0195-3383
dc.authoridYilmaz, Yakup Berkay/0000-0001-8989-8045
dc.contributor.authorKurt, Begum
dc.contributor.authorOzleyen, Adem
dc.contributor.authorAntika, Gizem
dc.contributor.authorYilmaz, Yakup Berkay
dc.contributor.authorTumer, Tugba Boyunegmez
dc.date.accessioned2025-01-27T20:38:59Z
dc.date.available2025-01-27T20:38:59Z
dc.date.issued2020
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractNeuropathological changes in Alzheimer's disease (AD) are directly linked to the early inflammatory microenvironment in the brain. Therefore, disease-modifying agents targeting neuroinflammation may open up new avenues in the treatment of AD. Strigolactones (SLs), subclasses of structurally diverse and biologically active apocarotenoids, have been recently identified as novel phytohormones. In spite of the remarkable anticancer capacity shown by SLs, their effects on the brain remained unexplored. Herein, the SIM-A9 microglial cell line was used as a phenotypic screening tool to search for the representative SL, GR24, demonstrating marked potency in the suppression of lipopolysaccharide (LPS)-induced neuroinflammatory/neurotoxic mediators by regulating NF-kappa B, Nrf2, and PPAR gamma signaling. GR24 also in the brain endothelial cell line bEnd.3 mitigated the LPS-increased permeability as evidenced by reduced Evans' blue extravasation through enhancing the expression of tight junction protein, occludin. Collectively, the present work shows the anti-neuroinflammatory and glia/neuroprotective properties of GR24, making SLs promising scaffolds for the development of novel anti-AD candidates.
dc.description.sponsorshipTechnological and Scientific Research Council of Turkey [218S814]
dc.description.sponsorshipStudies were supported by Technological and Scientific Research Council of Turkey (Grant No. 218S814).
dc.identifier.doi10.1021/acschemneuro.9b00694
dc.identifier.endpage507
dc.identifier.issn1948-7193
dc.identifier.issue4
dc.identifier.pmid32017526
dc.identifier.scopus2-s2.0-85080116658
dc.identifier.scopusqualityQ1
dc.identifier.startpage501
dc.identifier.urihttps://doi.org/10.1021/acschemneuro.9b00694
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23826
dc.identifier.volume11
dc.identifier.wosWOS:000515195800002
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAmer Chemical Soc
dc.relation.ispartofAcs Chemical Neuroscience
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectAlzheimer's disease
dc.subjectneuroinflammation
dc.subjectneuroprotective
dc.subjectmicroglia
dc.subjectstrigolactones
dc.subjectcarotenoids
dc.titleMultitarget Profiling of a Strigolactone Analogue for Early Events of Alzheimer's Disease: In Vitro Therapeutic Activities against Neuroinflammation
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu